Deutsche Biotech Innovativ AG

DB:DBI Stock Report

Market Cap: €4.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Deutsche Biotech Innovativ Valuation

Is DBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DBI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DBI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DBI?

Key metric: As DBI is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for DBI. This is calculated by dividing DBI's market cap by their current book value.
What is DBI's PB Ratio?
PB Ratio6.7x
Book€681.40k
Market Cap€4.55m

Price to Book Ratio vs Peers

How does DBI's PB Ratio compare to its peers?

The above table shows the PB ratio for DBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12x
CNW co.don
1xn/a€6.5m
MDG1 Medigene
0.8x11.0%€15.2m
T5O bioXXmed
6.2xn/a€673.0k
VSC 4SC
39.9xn/a€42.2m
DBI Deutsche Biotech Innovativ
6.7xn/a€4.5m

Price-To-Book vs Peers: DBI is expensive based on its Price-To-Book Ratio (6.7x) compared to the peer average (0.8x).

Price to Book Ratio vs Industry

How does DBI's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
DBI 6.7xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: DBI is expensive based on its Price-To-Book Ratio (6.7x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is DBI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DBI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DBI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/24 00:16
End of Day Share Price 2023/09/26 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Deutsche Biotech Innovativ AG is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon ScholesFirst Berlin Equity Research GmbH